ArticleInfection and drug resistance2019
Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses.
Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04887636 (Baseline Study of Vaginal Microbiota in Healthy Chinses Female Population), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Baseline Study of Vaginal Microbiota in Healthy Chinses Female Population
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial.BMC women's health · 2023Trial
- Identifying a Vaginal Microbiome-Derived Selective Antibiotic Metabolite via Microbiome Pharmacology Analysis.bioRxiv : the preprint server for biology · 2025Article
- Bacterial vaginosis.Nature reviews. Disease primers · 2025Review
- Article
- Effect of Metronidazole on Concentrations of Vaginal Bacteria Associated with Risk of HIV Acquisition.Research square · 2024Article
- Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA.Journal of comparative effectiveness research · 2024Article
- Vaginal epithelial dysfunction is mediated by the microbiome, metabolome, and mTOR signaling.Cell reports · 2023Article
- Bacterial Vaginosis-Vaginal Polymicrobial Biofilms and Dysbiosis.Deutsches Arzteblatt international · 2023Review
- Impact of (recurrent) bacterial vaginosis on quality of life and the need for accessible alternative treatments.BMC women's health · 2023Article
- Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians.International journal of women's health · 2023Review
- The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Article
- Gut and vaginal microbiomes on steroids: implications for women's health.Trends in endocrinology and metabolism: TEM · 2021Review
- Article
- Daily Vaginal Microbiota Fluctuations Associated with Natural Hormonal Cycle, Contraceptives, Diet, and Exercise.mSphere · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOral metronidazole therapy is the standard of care for bacterial vaginosis (BV), yet it has alarming rates of recurrence and refractory responses among recurrent BV (RBV) patients. This study addresses whether high dose vaginal metronidazole therapy (HDM) is beneficial in RBV patients who fail after standard of care (SOC) therapy, whether diagnostic test scores proximal to the HDM predict clinical outcome, and whether menses, coitus, or race influences therapy outcome. PATIENTS AND
methodsA total of 90 patients with RBV were given SOC and tracked 74 for up to 9 months. Refractory or recurrent patients (57) with symptomatic BV were given HDM and followed for up to 8 months. Patients were evaluated by Amsel criteria, Nugent score, and a qPCR assay that assesses the
resultsHDM achieved at least short-term remission in 68% of the patients who were refractory to or recurred after SOC and provided a 10-day increase in the mean duration of remission among patients who eventually recurred (
conclusionEncouraging results obtained with HDM justify a prospective, randomized study to determine if follow-up HDM is beneficial among a broader cohort of women failing conventional oral metronidazole therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.